Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gene rearrangements, and BRAF has led to an improvement in overall survival and progression-free survival by identifying subgroups of patients who benefit from targeted treatment; however, most NSCLC tumors lack these mutations.
NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of metastatic NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients with metastatic NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, or chemotherapy in combination with immunotherapy, including NSCLC that has progressed rapidly on initial therapy.
Through real-world clinical cases, this activity will review available treatment options and guideline recommendations for patients with advanced NSCLC without targetable activating mutations that has progressed on initial platinum-based therapy, or immunotherapy combined with chemotherapy, and available data that can inform treatment of NSCLC that progresses rapidly on initial therapy. Discussion will include real-world patient cases and clinical challenges including how the experts discerned the best treatment approaches based upon disease progression patterns, prior lines of therapy, unique patient characteristics, and wading through the vast amount of current/emerging evidence to arrive at the optimal treatment plan with their patients.